Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...

ANI Pharmaceuticals (NASDAQ:ANIP) lost ~8% in the premarket on Wednesday after the company announced a failure in a clinical ...

Aflibercept 8 mg is being jointly developed by Regeneron and Bayer AG. In the U.S., Regeneron maintains exclusive rights to EYLEA and aflibercept 8 mg. Bayer has licensed the exclusive marketing ...

Aflibercept is a recombinant human fusion protein that acts as a soluble decoy receptor for vascular endothelial growth factor (VEGF) family members VEGF-A, VEGF-B, and placental growth factor.

Aflibercept 8mg late-breaking data presented at Retina Society in diabetic macular edema and wet age-related macular degeneration. News release. Regeneron Pharmaceuticals, Inc. November 4, 2022.

EYLEA® (aflibercept) 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO ...

A non-inferiority comparison between aflibercept and bevacizumab as first-line treatment for macular edema associated with central retinal vein occlusion kicks off this summer, according to study ...

Eylea (aflibercept, Regeneron Pharmaceuticals), also known as VEGF Trap-Eye, is a synthetic anti-VEGF agent that was approved for treatment of wet age-related macular degeneration in November.

Eylea HD® (aflibercept) injection 8mg positive phase 3 results in patients with macular edema following retinal vein occlusion presented at Angiogenesis Meeting. News release.

Aflibercept is clearly an option for patients who are showing an incomplete anatomic response to other anti-VEGF agents," he noted. Dr. Recchia and colleagues presented results from a series of ...

--Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for Priority Review the Biologics License Application for aflibercept 8 mg for treatment ...